Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer

Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026.

Torsten Woehr, incoming CEO of Rentschler Biopharma, commented: “Rentschler Biopharma is recognized for its trusted partnerships, scientific expertise and unwavering commitment to delivery for clients. I am excited to lead the company and look forward to working alongside the talented and dedicated teams across the organization. We will build on this solid foundation to further enhance our capabilities and create lasting impact for our partners, our clients and patients worldwide. In doing so, we remain firmly guided by the vision of advancing medicine to save lives, together.”

The appointment advances the next phase of the company’s corporate strategy, aimed at further strengthening long-term growth and sustainable value creation. Following a period of interim leadership, Prof. Dr. Uwe Buecheler, will step down as interim CEO and return to his role as Vice Chairman of the Supervisory Board, effective August 1, 2026.